Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05555862Phase 2Active Not Recruiting

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

Role: collaborator

NCT00501306Completed

Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men

Role: lead

NCT01104181Not ApplicableCompleted

Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test

Role: lead

All 3 trials loaded